Highlights
A newly published Green Journal study followed over 500 men treated with moderately hypofractionated proton therapy for prostate cancer, with a median follow-up of more than a decade.
The results are steady—and important.
- 92% of patients remained free from disease progression at 10 years
- Nearly 96% for low-risk patients
- Very low rates of recurrence (just 3.6%)
Just as meaningful is how patients did during and after treatment:
- Low rates of side effects, with severe complications being rare
- No grade 4+ GI or GU toxicities reported
- A low incidence of secondary cancers, especially within the treated area
Proton therapy continues to show not just effectiveness, but durability.
It’s not just about getting through treatment. It’s about how patients do years later.
As Dr. John Chang, Medical Director at the Oklahoma Proton Center, often says:
“The goal isn’t just to treat the cancer. It’s to protect the life around it—how someone lives during treatment, and long after it’s over.”
At the Oklahoma Proton Center, these principles are reflected in a clinically driven approach to care delivery. With more than 15 years of operational experience and a high-volume proton therapy program, the center emphasizes precision treatment planning, evidence-based protocols, and consistent treatment execution. This includes the use of advanced image guidance, standardized workflows, and a multidisciplinary care model designed to optimize outcomes while minimizing treatment-related toxicity.
And after 10+ years, the story remains consistent:
Strong control. Minimal toxicity. Meaningful long-term outcomes.
To learn more about proton therapy or to schedule a consultation:
📞 Call us at 405-773-6700
🌐 Or visit our Contact Us form to connect with our team
